insulin aspart

Insulin aspart is an FDA-approved medication used to improve glycemic control in adults and children with type-1 and type-2 diabetes mellitus. It is also sometimes used off-label to treat diabetic ketoacidosis.

In individuals diagnosed with diabetes, the absorption rate of insulin aspart (IAsp) (NovoRapid, Novo Nordisk, Denmark) is faster compared to regular human insulin (RHI). This results in higher peak concentration levels and a shorter time to reach peak concentration. However, the overall absorption, as measured by the area under the concentration-time curve, is similar for both IAsp and RHI.

Insulin Type Onset Peak Time

Rapid-acting inhaled 10 to 15 minutes 30 minutes

Regular/short acting 30 minutes 2 to 3 hours

Intermediate acting 2 to 4 hours 4 to 12 hours

Long acting 2 hours Does not peak

Fiasp is a more recent version of NovoLog that includes niacinamide, a form of vitamin B3. The addition of niacinamide helps insulin to be absorbed more quickly, leading to a faster onset of action in the bloodstream, typically around 2.5 minutes after it is administered.

Insulin Aspart, sold under various brand names such as NovoLog, NovoLog FlexPen, NovoPen Echo, NovoLog FlexTouch, and Fiasp, is a prescription drug prescribed for the treatment of both Type 1 and Type 2 Diabetes Mellitus.

Types of insulin include rapid-acting, short-acting, intermediate-acting, mixed, and long-acting.

Fast-acting insulin (Humalog) begins to take effect 15 minutes after injection, reaches its peak in 1 to 2 hours, and remains active for 2 to 4 hours.

NovoLog is a fast-acting insulin that should be injected under the skin 5 to 10 minutes before eating. Make sure to have your meal ready before injecting. After taking the insulin, do not miss a meal or wait too long to eat. Prepare your insulin carefully.

Fast-acting insulin aspart, also known as faster aspart, is a new version of insulin aspart that includes niacinamide and L-arginine as additional ingredients. This formulation of insulin aspart has the advantage of providing a quicker onset of insulin action and a more pronounced effect in lowering blood glucose levels compared to regular insulin aspart.

Humalog and NovoLog are brand names for insulin lispro and insulin aspart, respectively. Both medications begin to take effect approximately 15 minutes after injection, reach their peak effectiveness after about 1 hour, and continue to work for 2 to 4 hours.

The CGMS data from the current study indicated that lispro and aspart had comparable effects on blood glucose fluctuation and hypoglycemia. There were no notable differences observed in MAGE, 24-hour MBG, SDBG, fasting blood glucose, and NGE between the two groups of patients with newly diagnosed T2DM.

Which is better, Humalog or Novolog? Both Humalog and Novolog are rapid-acting insulins that are equally effective. They are administered in the same manner and have similar side effects, such as hypoglycemia (low blood sugar). However, Novolog has a slightly faster onset of action and should be taken 5 to 10 minutes before meals.

In addition, both medications have similar side effects and can interact with other drugs. However, there are notable distinctions between these two brands. Specifically, Humalog and NovoLog cannot be substituted for one another as they contain different types of insulin. Humalog contains insulin lispro, whereas NovoLog contains insulin aspart.

Fiasp is a more recent version of NovoLog that includes niacinamide, a form of vitamin B3. The addition of niacinamide helps insulin to be absorbed more quickly, leading to a faster onset of action in the bloodstream, typically around 2.5 minutes after it is administered.

In studies with adults, Lyumjev demonstrated superior reduction of blood sugar spikes compared to Humalog 1 and 2 hours after meals. Due to its rapid action, it is recommended to take Lyumjev at the beginning of a meal or within 20 minutes after starting a meal.

Symptoms of hypoglycemia and an allergy to insulin lispro products or any of their ingredients.

Indeed, there is a dosage conversion available for transitioning from NovoLog to Humalog (insulin lispro). Both medications are classified as rapid-acting insulins and serve the purpose of controlling blood sugar spikes that occur during meals, similar to NovoLog.

Humalog, by rearranging the sequence of two amino acids (proline at B-28 and lysine at B-29), is absorbed more quickly and has a shorter duration compared to Humulin. This allows for administration within 15 minutes of a meal, making it more convenient and less likely to cause hypoglycemia.

In individuals diagnosed with diabetes, the absorption rate of insulin aspart (IAsp) (NovoRapid, Novo Nordisk, Denmark) is faster compared to regular human insulin (RHI). This results in higher peak concentration levels and a shorter time to reach peak concentration. However, the overall absorption, as measured by the area under the concentration-time curve, is similar for both IAsp and RHI.

Lantus and Humalog are two types of insulin used to treat both type 1 and type 2 diabetes. One distinction between the two is that Humalog is typically administered alongside another long-acting insulin.

Understanding the mechanisms of Humalog and Lantus will assist in resolving Tina’s issue. Humalog, a rapid-acting insulin, initiates its effects within 15 to 30 minutes of administration and remains active for 3-4 hours. On the other hand, Lantus is a slow-acting insulin that commences its action approximately 1-2 hours after injection and persists in the body for 20 to 24 hours.

Humalog, a rapid-acting insulin, has a quicker onset and shorter duration compared to regular human insulin. It is administered either 15 minutes before or immediately after a meal.

NovoLog, also known as insulin aspart, is a rapid-acting insulin medication that doctors may prescribe to individuals with either Type 1 or Type 2 diabetes.

Fiasp is a more recent version of NovoLog that includes niacinamide, a form of vitamin B3. The addition of niacinamide helps insulin to be absorbed more quickly, leading to a faster onset of action in the bloodstream, typically around 2.5 minutes after it is administered.

Insulin Glargine is an insulin analog that acts similarly to normal basal insulin secretion, providing a steady release without significant peaks. It is commonly used in combination with Insulin Aspart, which is a rapid-acting insulin that is partially bound to protamine and has both soluble and intermediate-acting properties.

Insulin aspart, also known as NovoLog, is a rapid-acting insulin medication prescribed for individuals with type 1 diabetes.

Insulin lispro, a rapid-acting insulin, aids in converting the food we consume into energy. It accomplishes this by utilizing the glucose present in the bloodstream as immediate fuel. Additionally, insulin facilitates the storage of energy for future use.

Fiasp® is a new formulation of insulin aspart that includes two additional ingredients, nicotinamide and L-arginine hydrochloride. These ingredients are not present in the original NovoRapid® formulation of insulin aspart. Nicotinamide is also known as niacinamide or vitamin B3, while L-arginine hydrochloride is an amino acid.

Insulin aspart exhibits a quicker absorption, onset of action, and shorter duration of action than regular human insulin when administered subcutaneously. It achieves peak concentration within 40-50 minutes.

Basaglar, also known as insulin glargine, is a medication that functions as an insulin hormone. Its primary purpose is to decrease the levels of glucose (sugar) in the bloodstream.

NovoLog® is a fast-acting insulin that assists in reducing blood sugar spikes after meals in both adults and children with diabetes. It has been demonstrated to effectively manage high blood sugar levels when used in conjunction with a long-acting insulin.

Insulin glargine is a medication that requires a prescription and is administered through self-injection. It is marketed under the brand names Lantus, Basaglar, and Toujeo, and there is currently no generic version available.

Humalog is a type of insulin that works quickly. It is typically used in combination with a longer-acting insulin for individuals with type 1 diabetes, unless they are using an external insulin pump. Humalog is effective in covering insulin needs for meals consumed within 30 minutes after injection, making it a suitable choice for mealtime insulin.

Official answer: NPH insulin, such as Humulin N and Novolin N, is commonly prescribed for both type 1 and type 2 diabetics to regulate blood glucose levels. This intermediate-acting insulin typically enters the bloodstream within 1 to 3 hours after injection, reaches its peak effect 4 to 12 hours later, and remains effective for approximately 12 to 16 hours.

Objective: The objective of this study is to report the pharmacokinetics of insulin glargine and its primary active metabolite, glargine-M1, when used in combination with supra-therapeutic doses of rapid-acting insulin aspart.

Type of InsulinOnsetPeakFast-actingRegular1-1 hr2-4 hrLyspro/ Aspart/ Glulisine<15 min1-2 hrIntermediate-acting

Lyumjev is a rapid-acting insulin designed to regulate blood sugar levels following meals, mimicking the function of natural insulin in individuals without diabetes.

To bring your blood sugar down to the target of 120 mg/dl, you would need to take 2 units of medication.

In individuals diagnosed with diabetes, the absorption rate of insulin aspart (IAsp) (NovoRapid, Novo Nordisk, Denmark) is faster compared to regular human insulin (RHI). This results in higher peak concentration levels and a shorter time to reach peak concentration. However, the overall absorption, as measured by the area under the concentration-time curve, is similar for both IAsp and RHI.

Fiasp is a more recent version of NovoLog that includes niacinamide, a form of vitamin B3. The addition of niacinamide helps insulin to be absorbed more quickly, leading to a faster onset of action in the bloodstream, typically around 2.5 minutes after it is administered.

Neutral protamine Hagedorn (NPH) insulin, named after its inventor Hans Christian Hagedorn, reaches its peak effect in 6 to 8 hours and can last up to 12 hours. It is commonly used to control blood sugar levels between meals and overnight.

Insulin Name | Expiration Upon Opening or Removing from Refrigerator
Insulin Aspart (Novolog) | 28 days
Insulin Aspart; Insulin Aspart Protamine (Novolog Mix 70/30) | 14 days
Isophane Insulin (NPH)-Novolin N | 28 days
Regular Insulin (Novolin R) | 28 days

The estimated total daily insulin requirements range from 0.5 to 1 unit per kilogram per day. The duration of action can vary depending on factors such as the dose, injection site, blood flow, temperature, and level of physical activity.

Lyumjev, also known as insulin lispro or insulin lispro-aabc, is a rapid-acting insulin used to manage blood sugar levels during meals for individuals with type 1 or type 2 diabetes. It is exclusively sold as a branded medication and is a biosimilar to Humalog (insulin lispro).

Insulin Preparation
Onset of Action
Peak Action
Regular: 30-60 minutes
2-4 hours
Intermediate-acting Insulin isophane (NPH): About 2 hours
4-12 hours
U-500 regular: 30 minutes
4-8 hours